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Lactoperoxidase is a member of the family of the mammalian heme peroxidases which have a broad spectrum of activity. Their
best known effect is their antimicrobial activity that arouses much interest in in vivo and in vitro applications. In this context, the
proper use of lactoperoxidase needs a good understanding of its mode of action, of the factors that favor or limit its activity, and
of the features and properties of the active molecules. The first part of this review describes briefly the classification of mammalian
peroxidases and their role in the human immune system and in host cell damage. The second part summarizes present knowledge
on the mode of action of lactoperoxidase, with special focus on the characteristics to be taken into account for in vitro or in vivo
antimicrobial use. The last part looks upon the characteristics of the active molecule produced by lactoperoxidase in the presence
of thiocyanate and/or iodide with implication(s) on its antimicrobial activity.
1. Introduction
Mammalian peroxidases are distinct from plant peroxidases
in size, amino acid homologies, nature of the prosthetic
group, and binding of the prosthetic group to the protein.
Plant peroxidases consist of approximately 300 amino acids
with a noncovalently bound heme moiety, while mammalian
peroxidases have 576 to 738 amino acids with a cova-
lently bound heme moiety [1]. Animals’ peroxidases display
high sequence homology compared to plant peroxidases [2,
3]. Mammalian peroxidases can detoxify peroxide, protect
against pathogens, and induce the production of thyroid
hormones, while plant peroxidases trigger defense reactions
against pathogens and stress, remove hydrogen peroxide, and
are involved in the metabolism of lignin and auxin and in the
oxidation of toxic reductors [1].
Based on amino acids homologies, peroxidases are now
classified into two superfamilies. The first superfamily clus-
ters peroxidases from plant, archea bacteria, and fungi and is
classified into three classes. Class I is composed of intracellu-
lar peroxidases such as yeast cytochrome 𝑐 peroxidase, ascor-
bate peroxidase, and catalase peroxidase, Class II is formed
by secretory fungal peroxidases such as manganese and
lignin peroxidases, and Class III consists in secretory plant
peroxidases including one of the most studied peroxidases,
the horseradish peroxidase [4, 5].The second one is called the
peroxidase-cyclooxygenase superfamily and clusters mam-
malian peroxidases together with protein from invertebrate,
bacterial, plant, and fungal species and other metalloproteins
such as cyclooxygenase [5]. This latter superfamily originally
called “themyeloperoxidase family” shares a domain of about
500 amino acids corresponding to the catalytic site [6] and is
classified into several subfamilies; one of them is the chordata
peroxidases in which the mammalian peroxidases are found
[5]. The main clades are the myeloperoxidases (MPO), eos-
inophil peroxidases (EPO), and the lactoperoxidase (LPO)
branch. Another clade consists in thyroid peroxidase (TPO)
which is distantly related to MPO, EPO, and LPO [5].
MPO is a lysosomal constituent in neutrophils and
macrophages and displays antimicrobial activity during the
postinfection inflammatory process but is also involved in
acute inflammatory diseases and in other pathologies such as
atherosclerosis [7–10]. EPO is secreted in eosinophils and dis-
plays cytotoxic activity against parasites, bacteria, and fungi.
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It could be associated to allergic eosinophilic inflammatory
disease pathologies [1, 10, 11]. LPO and salivary peroxidase
are found in secretions of exocrine glands and are associated
to antibacterial and antifungal activity [12–14]. Finally, TPO
is a membrane enzyme localized in thyroid follicle cells that
takes part in the synthesis of thyroid hormones [1].
This review summarizes present knowledge on the mode
of action of lactoperoxidase which can be extended to the
mammalian peroxidases mode of action and on the specific
interaction of LPO with thiocyanate and iodide, together or
alone, with implications on its antimicrobial activity.
2. Mode of Action of Lactoperoxidase
LPO is a calcium- and iron-containing glycoprotein arranged
in a single polypeptide chain of about 80 kDa [15, 18, 19].
Human LPO is moderately cationic with a pI of ca. 7.5 but
bovine LPO is more cationic with a pI of ca. 9.6 [18, 19].
MPO is a highly cationic (pI of ca. 10) dimeric protein of
146 kDa, eachmonomer containing one calcium and iron and
joined together by a disulfide bridge [18]. The ion calcium
plays an important role in the stability of both enzymes
[19, 20]. The active site in LPO, MPO, EPO, and TPO is the
heme which consists in a protoporphyrin IX derivative fixed
covalently through two ester linkages via a conserved distal
aspartate and glutamate residues, a third link being present
in MPO and consisting in a thioether sulfonium bond with
a methionine [4, 15, 19, 21]. These covalent bonds, which are
specific for vertebrate peroxidases, result in a distortion of the
symmetry and planarity of the prosthetic group and give the
unique spectroscopic and redox properties of these proteins
[4, 20, 21]. The proximal heme ligand is a highly conserved
histidine residue which is hydrogen bonded to a conserved
asparagine residue that acts as hydrogen-bond acceptor
[20, 22]. On the distal heme site, a conserved histidine-
arginine couple plays a role in the proton transfer during
the formation of Compound I, and a conserved glutamine
residue and several conserved water molecules are involved
in a hydrogen-bond network acting in halide delivery and
binding [4, 18, 20]. A conserved asparagine residue in LPO,
EPO, and MPO located close to the distal histidine seems
also critical for the catalysismechanism [18, 20].The substrate
channel in LPO is narrower, longer, and more hydrophobic
compared toMPOwith the consequence that the LPO-active
site seems to be less exposed to surrounding media [22, 23].
Heme peroxidases are oxidoreductase enzymes that act
through different reactionmechanisms. Although some char-
acteristics are specific to a member of the family, the same
global procedure is followed by all members. The cycle
begins with the transformation of the native enzyme into
Compound I. Afterwards, and dependingmainly on substrate
concentrations, Compound I enters the halogenation cycle or
the peroxidase cycle which both end by the enzyme returning
to its native state (see Figure 1).
2.1. Formation of Compound I. The first reaction of the
native enzyme starts in the presence of hydrogen peroxide,
which acts as a relatively specific electron acceptor [24].
Native enzyme
Compound I








Oxidation state of compounds I or II with regard to the native 











AH/A∙ : one-electron substrate/oxidized one-electron substrate
X−/OX− : (pseudo)halogen/oxidized (pseudo)halogen
Figure 1: Halogenation or peroxidase cycle of peroxidases Com-
pound I.
Other substrates have been described, such as ethyl hydroper-
oxide, peroxyacetic acid, cumene hydroperoxide, and 3-
chloroperoxybenzoic acid [20, 25]. Compound I is formed as
follows:








The native enzyme undergoes a two-electron oxidation.
Two electrons are transferred from the enzyme to hydrogen
peroxide which is reduced into water. Compound I is two
oxidizing equivalents above the native enzyme: one is in the
oxyferryl heme center and the other is present as an organic
cation located on the porphyrin ring [4, 26, 27]. Compound
I is not specific regarding the electron donor [24] and the
composition of the medium determines its subsequent cycle
(see Figure 1). As Compound I is very unstable, an amino
acid residue of the apoprotein is oxidized in the absence
of an exogenous electron donor [14]. This reaction yields
Compound I isomer that is very similar to Compound II
regarding its iron redox state and its incapability to react with
halogens [20].
2.2. The Halogenation Cycle. In the presence of a halogen
(Cl−, Br−, or I−) or a pseudohalogen (SCN−), Compound I
is reduced back to its native enzymatic form through a two-
electron transfer while the (pseudo)halogen is oxidized into
a hypo(pseudo)halide (see Figure 1). Hypo(pseudo)halides
(OX−) are powerful oxidants with antimicrobial activity [14,
28–32]. The halogenation cycle is described by the following
reaction:
Compound I + X− (halogen or pseudo-halogen)
󳨀→ Native enzyme +OX−
(2)
The oxidation rate of halogens by peroxidase-derived
Compound I depends on various factors. One of these factors
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Cl− Cl− Br− Br− I− I− SCN−SCN−
MPO: myeloperoxidase, LPO: lactoperoxidase
MPO Compound I apparent second-order rate constant at
LPO Compound I apparent second-order rate constant at
Cl− : chloride, Br− : bromide, I− : iodide, and SCN− : thiocyanate
pH 7 from [16]
pH 7 from [15]
Figure 2: Apparent second-order rate constant at pH 7 (×104M−1 s−1) of the reaction between myeloperoxidase Compound I or lactoper-
oxidase Compound I with (pseudo)halides [15, 16].
is the standard reduction potential of the enzyme, which
differs among peroxidases and plays a role in their capacity
to oxidize specific (pseudo)halides. The redox reaction can
occur only if the reduction potential of the enzyme is equal
or superior to the reduction potential of the substrate. The
standard reduction potential at pH 7 of Compound I perox-
idases and the couple of two-electron reduction HOX/X− is
ranking in the following ascending rank: LPOCompound I <
EPO Compound I < MPO Compound I; HOSCN/SCN− <
HOI/I− ≪ HOBr/Br− < HOCl−/Cl− [17, 18, 33, 34]. This
involves that only the MPO Compound I is able to oxidize
Cl− with appropriate rates, LPO being able to oxidize with
high rates I− and SCN− and slowly Br− [16, 17, 20, 33, 34].
Interestingly, although LPO Compound I has the lowest
reduction potential compared to EPOCompound I andMPO
Compound I, it catalyzes the oxidation of I− and SCN− with
the highest rates (Figure 2) [15–17, 20]. This suggests that
other factors play a role, such as anion size, anion access, and
anion binding as well as structural and amino acid differences
in the active and binding site between enzymes [17, 18, 20].
The reduction potential of the Compound I/native
enzyme and HOX/X− redox couples depends on reactant
concentrations and pH values. At a specific reactant concen-
tration, it decreases with increasing pH values, but slopes
differ (Figure 3) [17]. This means that there exists a threshold
pH value above which the oxidation of halides becomes
thermodynamically unfavorable, especially for halides with
high reduction potential such as Cl− and Br− [17].
Concentrations of (pseudo)halogens also affect their
affinity to Compound I (Figure 4).
Although plasma Cl− concentrations are 1,000-fold
higher than Br− and SCN−, MPO Compound I oxidizes


















Figure 3: Illustration (according to [17]) of the pH threshold
value above which the oxidation of the halogen by mammalian
heme peroxidase will be thermodically unfavorable. The reduction
potential of the couple Compound I/native enzyme and the couple
halogen (X = chloride, bromide) HOX/OX− is expressed with an
illustrative function of the pH, at a specific concentration of enzyme
and substrates.
preferentially oxidizes SCN− in the presence of physiological
concentrations of SCN−, Br−, and I− [36]. In the saliva
of healthy adults, where Cl− concentrations are only about
25-fold higher than SCN−, SPO Compound I and MPO
Compound I primarily generate hypothiocyanite [37, 38].
The levels of I− in human milk, saliva, blood, and tissues
except the thyroid gland are below 1𝜇M and its in vivo
oxidation by Compound I is negligible [17, 38]. In human
milk, peroxidase activity is only derived from leucocytes. As







































Figure 4: Illustration of the interaction between the biodisponibility of a peroxidase, the (pseudo)halogen concentration in plasma, in saliva,
and in milk, and the production of oxidant molecules. MPO: myeloperoxidase; SPO: salivary peroxidase; LPO: bovine lactoperoxidase;
OCl−: hypochlorite; and OSCN−: hypothiocyanite. Although chloride is the most available substrate compared to thiocyanate, bromide, and
iodide, thiocyanate is the most effective substrate for the Compound I and hypothiocyanite could be produced at equal or superior levels
compared to hypohalides.
high, oxidation of Cl− is possible although it has never been
reported [14]. In bovine milk, lactoperoxidase is an abundant
enzyme, and with mean concentrations of I− and SCN− of
310 𝜇g/kg and 0.2–15mg/kg, respectively, oxidation is possi-
ble [19, 39]. Nevertheless, the relative abundance of SCN− in
all secretions, blood, and tissues and its better capacity as an
electron donor make it one of the main in vivo substrates
of Compound I lactoperoxidase and myeloperoxidase for
2-electron oxidation compared to halides [15]. In in vitro
applications, the ratio between (pseudo)halides regulates the
ratio of hypohalides generated by the reaction. However, as
SCN− is the most effective substrate for Compound I, its
presence, even in small quantities, enhances its oxidation
[14, 35, 36].
2.3. The Peroxidase Cycle. Alternatively, Compound I can
shift to the peroxidase cycle, which consists of two sequen-
tial one-electron transfers back to the enzyme that yield
(i) Compound II and (ii) the native enzyme, while the
substrate is oxidized into a radical (Figure 1) [40–42]. The
peroxidase cycle is summarized in the following equations:
Compound I + AH 󳨀→ Compound II + A∙
Compound II + AH 󳨀→ Native enzyme + A∙
(3)
Compound I is not specific regarding the one-electron
donor; it can be exogenous or endogenous, and a lot of candi-
dates have been described [18, 20, 43].Hydrogen peroxide can
undergo a one-electron oxidation onlywithMPOCompound
I, with the formation of superoxide [16, 20, 44, 45].
During the first step of the peroxidase cycle, the cation
located in the porphyrin ring undergoes a one-electron
reduction with formation of Compound II and concomitant
oxidizing of one one-electron substrate [4, 24]. Compound II
maintains one oxidizing equivalent in the oxyferryl center
[4, 24]. Finally, this latter is reduced back to the native enzyme
with the oxidation of a second one-electron donor.
The standard reduction potential of the couple Com-
pound I/Compound II is high and allowed the one-electron
oxidation by Compound I of a wide range of substrates
[18, 20]. In contrast, the standard reduction potential of the
couple Compound II/native enzyme is low and restrains the
numbers of possible substrates for Compound II [18, 20].
With the result that (i) the Compound II/native enzyme
standard reduction potential is too low to react with halogens
and (ii) the nature of substrates strongly influenced their
ability to be oxidized by mammalian peroxidase compound
II [2, 14, 20], therefore, when the enzyme is in this state, it has
to be first reduced to the ground state before possibly partici-
pating to the halogenation cycle and producing antimicrobial
molecules [14]. Moreover, the reduction of Compound II to
the ground state is the rate-limiting step [45, 46]; that is, the
peroxidase cycle interferes with the halogenation cycle and
slows down antimicrobial activity [47].
The peroxidase cycle has been described as a possible
catalytic sink for nitric oxide (NO) [46] but also for hydrogen





to LPO [24]. Increase of NO removal from media, even
in presence of Cl−, after addition of MPO, EPO, or LPO
and accelerated rates of Compound I and Compound II
reduction in presence of NO show that peroxidases may
regulate the bioavailability of NO [46]. In conditions of
high excess of hydrogen peroxide relative to LPO and in
the absence of an exogenous electron donor, Compound
II is transformed into Compound III which is 3 oxidative
equivalents above the native enzyme. In moderate excess
conditions, Compound III can be partially reconverted into
Compound II and can reenter the peroxidase cycle [24, 40].
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Otherwise, the enzyme is irreversibly inactivated; the heme
fraction is cleaved and iron is released [48]. In the presence
of an exogenous two-electron donor, the enzyme is largely
protected from hydrogen peroxide because the halogenation
cycle is favored. Furthermore, protection is higher with





oxygen and iodide in a reaction called the pseudocatalytic
activity of peroxidase [24, 40, 49].
However, thiocyanate can act as a one-electron donor and
be part of the peroxidase cycle, with the sequential formation
of two thiocyanate radicals [47]. With 200𝜇M SCN−, LPO
is predominantly in its native form; this indicates that the
halogenation cycle prevails [47].
In the presence of both one- and two-electron donors,
competition for oxidation can occur and favor the halogena-
tion or the peroxidase cycle. The presence of EDTA inhibits
the oxidation of iodide due to competition for binding to
Compound I [50]. The standard reduction potential between
the donors favors the molecule with the lowest reduction
potential. Thereby, the respective reduction potentials of the
one- and two-electron oxidation of thiocyanate at very low
pH are 1.65V and 0.82V and promote the halogenation
cycle [51]. In the case of low concentrations of halides or
thiocyanate, below 10 𝜇M I− or 3 𝜇M SCN−, Compound
I reacts with any suitable exogenous or endogenous one-
electron donor, with the subsequent formation of Compound
II and a negligible oxidation rate of halides and thiocyanate
[14].
2.4. Inhibition of the Function of Mammalian Heme Peroxi-
dase. The function of heme peroxidases can be inhibited in
several ways that could be classified into three categories.
The first one could represent an inhibition of the enzyme
by (i) molecules or proteins and (ii) external conditions
such as pH and temperature. For example, cyanide, azide,
nitrite, mercaptomethylimidazole, thiourea, superoxide, high
levels of nitric oxide, and high levels of thiocyanate bind
to the native enzyme and alter Compound I formation [20,
46, 47, 52–54]. With thiocyanate, inhibition is linked to the
restriction of the binding site to hydrogen peroxide and





or I− will inactivate irreversibly LPO
with liberation of free iron [48, 55]. Temperature between
73∘C and 83∘C, depending on the heating time, results in
unfolding and inactivation of LPO [19]. Extreme pH is
inactivating enzymes and at low pH an amino acid group,





[56]. Some proteases such as pepsin and pronase are
able to inactivate LPO by proteolysis but chymotrypsin did it
very slowly and trypsin and thermolysin are not active against
LPO [19].
The second group of inhibitors could concern substances
or proteins which are able to interfere with the catalytic





stop the formation of Compound I [30, 52]. Competition
between substrates can also interfere with the reaction cycle
such as SCN− which competes very effectively with Cl−, Br−,
and I− [52, 53]. HOCl has the capacity to bind to LPO native
enzyme and convert it into Compound I. Above 100 𝜇M,
HOCl mediates the destruction of the LPO heme center
[57].
The third class could be related to substances or pro-
teins which are buffering active molecules produced during
the catalytic reaction. For example, presence of thiosulfate,
thioglycolate, glutathione, dithiothreitol, cysteine,NAD(P)H,
and tyrosine will reduce the antimicrobial activity through
reacting with OCl−, OBr−, OI−, or OSCN− [52, 53, 58, 59].
The enzyme NADH-OSCN oxidoreductase is able to reduce
OSCN− in SCN− [60].
3. Activity of Lactoperoxidase with
Thiocyanate and/or Iodide
LPO concentrations in cow’s milk are around 30mg L−1
depending on season, diet, and calving and breeding season
[61]. LPO extraction from whey or milk is based on a
well-developed industrial process [62]. Compared to MPO
and EPO, LPO is easily isolated and manufactured in large
quantities. As a result, cow’s milk peroxidase is the favorite
molecule for in vitro or in vivo applications such as con-
servation of raw and pasteurized milk, storage of emulsions
and cosmetics, moisturizing gel and toothpaste in human dry
mouth, veterinary products, and preservation of foodstuffs
[19, 61, 63, 64].
3.1. Activity of LPO Related to Hypothiocyanite
3.1.1. Mode of Action of Hypothiocyanite. Thiocyanate is oxi-
dized in a two-electron reaction that yields hypothiocyanite.
Hypothiocyanite has a pKa of 5.3 [65]. It is more acidic than
hypohalides that have pKas of 7.5 (HOCl), 8.6 (HOBr), and
10.6 (HOI) [14, 66]. All hypo(pseudo)halides (OX−) are in an
acid-base equilibrium association with their corresponding
acid hypo(pseudo)halide (HOX). For example, in the case of
hypothiocyanite,
HOSCN 󴀗󴀰 OSCN− +H+ (4)
The acid form has a higher oxidation potential and is
more soluble in nonpolar media so that it passes through
hydrophobic barriers such as cell membranes more easily
but it is less stable than the basic form (OX−) [14, 66].
Hypohalide acids are predominant in acidic to neutral media
and even in basic conditions for HOBr and HOI, whereas
hypothiocyanite needs a pH below 5.3 to be predominant in
the acid form [66, 67].
SCN− is the two-electron donorwith the lowest reduction
potential and therefore forms the hypothiocyanite acid with
the lowest oxidative power compared to hypohalous acids.
Hypohalous acids rank as follows, with increasing oxidative
strength: OSCN− < OI− < OBr− < OCl− [28, 66].
These characteristicsmake hypothiocyanite relatively specific
regarding its molecular target (Figure 5), that is, a thiol






- Reduced pyridine nucleotide




Figure 5: Target group of hypothiocyanite, hypoiodite, and iodine.
Due to its low oxidation power, hypothiocyanite is relatively specific
and is not reactive against all thiols. In vivo, hypoiodite seems to
be selectively directed against reduced pyridine nucleotide because
even the presence of excess glutathione and methionine does
not thoroughly inhibit their oxidation. HOSCN/OSCN−: acidic or













Figure 6: Illustration of the cofactor role of SCN− or I−. When
the necessary conditions are fulfilled, that is, (i) no substrate





and SCN− or I−, (iii) enough R-SH,
and (iv) no incorporation of SCN− or I− in stable byproducts, the










LPO: lactoperoxidase; R-SH: peptide or protein with a thiol moiety;
R-S-SCN or R-S-I sulfenyl thiocyanate or iodide; R-SOH: sulfenic
acid; OSCN−: hypothiocyanite; and OI−: hypoiodite.
Sulfhydryl oxidation by OSCN− generates sulfenyl thio-





+ LPO 󳨀→ OSCN− + LPO
R-SH +OSCN− 󳨀→ R-S-SCN +OH−
R-S-SCN +H
2
O 󳨀→ R-S-OH + SCN− +H+
(5)
The cycle of reactions shows that thiocyanate acts like
a cofactor for LPO (Figure 6) so that the total number of
oxidized sulfhydryls is independent of SCN− as long as
(i) thiocyanate is not exhausted, (ii) thiocyanate is not in
competition with other substrates for the binding to Com-
pound I, (iii) thiocyanate is not incorporated into an aromatic




is present, and (v) thiol moiety
is still available [68, 69].
Although the target of OSCN− is a thiol moiety, not
all sulfhydryls are equally sensitive to OSCN−; albumin,
cysteine, mercaptoethanol, dithiothreitol, glutathione, and 5-
thio-2-nitrobenzoic acid are all oxidized but 𝛽-lactoglobulin
is poorly oxidized, probably due to a limited accessibility of
sulfhydryls to OSCN− [68]. In some conditions, that is, the




and SCN−, and after the
oxidation of available sulfhydryls, modification of tyrosine,
tryptophan, and histidine protein residues can occur and that
could be linked to the formation of a labile powerful oxidant
such as sulfur dicyanide [68].
Some authors suggest that (SCN)
2
is formed during the
enzymatic reaction and then chemically hydrolyzed into
hypothiocyanite [14, 69, 70]. However, a recent publication
demonstrates that (SCN)
2
cannot be a precursor during the
enzymatic oxidation of SCN− at neutral pH inmammals [71].
Hypothiocyanite is less stable in acid conditions, with
high concentrations of SCN− and in the presence of (SCN)
2
,








A recent study, based notably on spectroscopic and chro-
matographic methods, proposes the following net equation







+ (1 − X) SO
3
2−
+ (1 − X)CNO−
+ 2SCN− + (5 − X)H+
(7)
The proportions of end anions were different at pH 4 and
pH 7; at pH 7, the proportion of CNO− was higher, SCN−
formation was slower, and no CN− was detected [71].
It might seem easier to produce hypothiocyanite chemi-
cally in in vitro applications, but producing hypothiocyanite





) or by a hypohalous acid (HOCl or HOBr) in basic media
is tricky due to overoxidation of SCN− [66]. The reference
method in the literature to produce 1- to 2-day stable OSCN−
is by hydrolyzing (SCN)
2
in basic conditions [72–74].
Hypothiocyanite inhibitors have been described. For
example CN−, a weak acid buffer, dissolved carbonate, excess
hydrogen peroxide, hydrofluoric acid, metallic ions, glyc-
erol, or ammonium sulfate accelerates the decomposition of
OSCN−, whereas sulfonamide stabilizes it [67, 72].
Appropriate concentrations of substrates induce en-
hanced activity [75].
3.1.2. Biological Activity of Hypothiocyanite. The biological
activity of hypothiocyanite is summarized in Figure 7.
The sulfhydryl moiety is essential for the activity
of numerous enzymes and proteins. Inhibition of bacte-
rial glycolysis through the oxidation of hexokinase, gly-
ceraldehyde-3-phosphate dehydrogenase (GAPDH), aldo-
lase, and glucose-6-phosphate dehydrogenase has been
observed [14, 51, 65, 70, 76]. Inhibition of respiration and
glucose transport is associated with the alteration of cell
membranes or transporters [14, 51, 65, 77]. Irreversible inhi-
bition is linked to long periods of incubation and bacterial
sensitivity depends on the bacterial species and on hypothio-
cyanite concentrations [14, 51, 59]. Increased concentrations
of reducing agents such as glutathione and cysteine can
reverse the inhibition through buffering hypothiocyanite
and converting the reduced thiol back into sulfhydryl [14,
78]. This defense mechanism is used by Escherichia coli; it
induces the CysJ promoter during the stress response to the
Enzyme Research 7
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Inhibition of glycolysis 
Inhibition of respiration
Inhibition of glucose transport
Possible defense mechanism of bacteria





- NAD(P)H-dependent reduction of OSCN−
Figure 7: Biological activity of hypothiocyanite on bacteria and possible defensemechanism of the bacteria. Reversible inhibition is observed
in that (i) hypothiocyanite is not reactive against all thiols and (ii) if hypothiocyanite is removed or diluted, the pathogen recovers. Irreversible
inhibition is linked to (i) long period of incubation, (ii) the bacterial species, and (iii) hypothiocyanite concentration. HOSCN/OSCN−: acidic
or basic form of hypothiocyanite and GSH: glutathione.
pH < 6
Influence of iodide concentration 
Influence of the pH







6 < pH < 9
HOI/I2OH/I2/I3
−











depend mainly on the concentration of iodide (upper part) and the pH (lower part). The species with an oxidant power are represented in
bold.
lactoperoxidase system [79]. Another resistance mechanism
could be the NAD(P)H-dependent reduction of OSCN−
without any loss of the sulfhydryl compound [14, 72, 78].
Alteration of the bacterial membrane increases the efficacy
of hypothiocyanite [80].
Furthermore, the activity of the entire system (enzyme +
substrates) is known to be more effective than hypothiocyan-
ite alone, whether enzymatically or chemically produced.
This has been explained by the production of short-lived,










[65, 73, 81]. The activity of hypothiocyanite
has been described against bacteria such as Actinomyces spp.,
Bacillus cereus, Lactobacillus spp., Staphylococcus albus, S.
aureus, Streptococcus spp., Escherichia coli, Legionella pneu-
mophila, Salmonella typhimurium, Pseudomonas fluorescens,
P. aeruginosa, Campylobacter jejuni, C. coli, and Listeria
monocytogenes [14, 32]. Reversible inhibition is observed
when cells recover after OSCN− is depleted [14, 59]. Irre-
versible inhibition is obtained with long-term incubation and
high level of OSCN− [59]. Higher concentration of SCN−
compared to I− is necessary to obtain inhibition against E. coli
and accumulation of OSCN− is observed as it is not reactive
against all thiols [59].Therefore, the activity of the SCN−-LPO
system appears to be more bacteriostatic than bactericidal.
3.2. Activity of LPO Related to Oxidized Iodide
3.2.1. Chemistry of Oxidized Iodide. Iodide is oxidized by
Compound I through a single two-electron transfer that
yields oxidized I− in the form of I
2
or HOI [14, 24, 82–85].
The active agent is composed of a mixture of species that are
not yet formally detailed due to the very complex behavior
and stability of I
2
and HOI in aqueous environments that
strongly depend on pH values and iodide concentrations
[66, 82, 83, 86].
8 Enzyme Research
Based on the inorganic chemistry of iodine in water
and literature on enzymatic oxidation of iodide, the active
molecules have been described as follows (Figure 8).










concentrations decrease with increasing
concentrations of I−. At an initial 1mM I
2
, with I−
concentrations ranging from 1mM to 100mM, I
2
concentrations fall from almost 1mM to 0,01mM, as




+ I− 󴀗󴀰 I
3
− (8)
(ii) In solution within a 6–9 pH range and with a max-







is formed in which I
3
− is not active and I
2
OH is
probably less reactive than HOI or I
2
[86, 87]. If
I− concentrations are above 10mM, I
3
− represents
the main species formed and the concentration of
active molecules relatively drops. The mechanism is
summarized in the following net equations:













(iii) In iodine solution, without iodide or when available
iodide has been oxidized, the number of I
2
-derived
molecules decreases with decreasing I
2
concentra-
tions. At 1,000 𝜇M I
2
, with pH-related ratios, five







and OI−). At 10 𝜇M I
2
, the main species are only I
2
,
HOI, and OI−, and HOI could represent up to 90% of
the active oxidant molecules at pH 8-9 [86]. Below a
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3
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(triiodide formation, independent of pH)
(10)
(iv) At high I− and 1% I
2





− are formed and represent 8.2%






















The stability of HOI and I
2
is linked to their dispro-
portionation in iodate, which has no oxidative activity in
neutral and basic pH conditions [86].The disproportionation
















stability increases at higher pHvalues andhigher iodide
concentrations [86]. In drinking water, HOI disproportion-
ation is slow and varies substantially; HOI has a half-life of
4 days to 3.5 years depending on (i) the initial level of HOI
that speeds its decomposition and (ii) the presence of borate,
phosphate, or carbonate that catalyzes its decomposition [88,
89].
3.2.2. Mode of Action of Oxidized Iodide. The oxidative
strength of I
2
is between that of the corresponding hypo-
halous acid HOI and the hypoiodite ion OI− and ranks as
follows: 0.485V (OI−) < 0.536V (I
2
) < 0.987V (HOI) [66].
HOI reacts through very rapid oxidation of thiol
groups, oxidation of NAD(P)H, oxidation of 𝛽-nicotinamide
mononucleotide, direct reaction with thioether groups
through sulfoxidation, and slow oxidation of the amine
moiety (Figure 5) [87, 90, 91]. At low I− concentrations,
iodination of tyrosine residues is catalyzed by the enzyme
[14]. In a cellular environment, HOI seems to be more selec-
tively directed against the degradation of reduced pyridine
nucleotides thanHOCL andHOBr because even the presence
of excess glutathione, methionine, or oxidized glutathione
does not thoroughly inhibit their oxidation [87].





peroxidase, (ii) no accumulation of oxidized iodide, and (iii)
no incorporation of iodide into stable byproducts such as
tyrosine residues, iodide acts as a cofactor (Figure 6) and















O + LPO (native enzyme)
R-SH + I
2
󳨀→ R-S-I + I− +H+
R-S-I+H
2
O 󳨀→ R-S-OH + I− +H+
(13)





inhibition of tyrosine iodation has been observed [83] and











tion 1) and production of I
3
− when excessive amounts of I−







+ 2I− + 2H+ (reaction 1)
I
2





Both reactions deplete the amount of the active oxidizing
agent I
2
. In the absence of tyrosine, oxidized iodide reacts







, IOH, and I
2
OH [82]. Some anions such as
Cl−, HPO
4





effect is inversely proportional to the concentration of I−;
above pH 9, I
2
is hydrolyzed and IO
3
− is formed [82].










[89] and through oxidation of I− byHOCl,
HOBr, or NH
2
Cl with a longer half-life [87, 89].
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Figure 9: Biological activity of hypoiodite or iodine on bacteria. Irreversible inhibition is observed and could be linked to (i) oxidation of
thiol groups, NAD(P)H, and thioether groups, (ii) high reactivity of HOI/I
2
against thiol and reduced nicotinamide nucleotides, and (iii) the
incorporation of iodide in tyrosine residue of protein (iodination of protein). HOI/OI−: acid or basic form of hypoiodite and I
2
: iodine.
3.2.3. Biological Action of Oxidized Iodide. The biological
action of oxidized iodide (Figure 9) is similar to that of
hypothiocyanite but differs in that (i) the reactivity of oxi-
dized iodide is complete against thiol group and (ii) cells did
not recover after removing of oxidized iodide [59].
Due to the cofactor role of I−, inhibition of respiration




, and I− is
complete with only 10𝜇M NaI, whereas 100 𝜇M of solely I
2
is necessary to obtain complete inhibition. This is directly
related to the oxidation of sulfhydryls, not to the percentage
of iodine incorporation [92, 93].
E. coli seems to be more sensitive if the bacteria are





and iodide) rather than adding several minutes after mixing
the enzyme with its substrates. This could be linked to the
formation of an unstable reactive intermediate [52].
The activity of the I− peroxidase system is more effective
against E. coli than the SCN− system, in that lower I−
concentrations are necessary, all sulfhydryls are oxidized, and
cells do not recover even if the amount of I
2
is not sufficient
to oxidize all SH groups [59, 80]. Against L. acidophilus,
high non physiological amounts of I− are necessary to obtain
inhibitionwhereas small concentrations of SCN− are effective
[70].
CN−, azide, EDTA, and SCN− inhibit the formation of
oxidized iodide [50, 52]. Increased pH values and increased
amounts of thiol and NAD(P)H compounds reduce the





-I− in presence of Streptococcus mitis is active





I− is active against Micrococcus, S. aureus, Listeria monocy-
togenes, Bacillus cereus, E. coli, and Candida albicans [12, 19,
80]. In the presence of other peroxidases, the I− peroxidase
system is active against Schistosoma mansoni, Fusarium
nucleatum, andActinobacillus actinomycetemcomitans [31, 95,
96]. Compared to SCN−, I−-LPO shows bactericidal activities
[14, 19, 80].
3.3. Activity of LPO Related to Hypoiodite and Hypothiocyan-
ite. The combination of SCN− with I− in the lactoperoxidase
system has been poorly studied. Tackling the enzymatic
mechanism is tricky, and contradictory results have been
found about microbial activity in the concomitant presence
of SCN− and I−.
In the presence of SCN− and I−, there is competition
between the two substrates for oxidation by lactoperoxidase
[14, 36]. I− alone exhibits bactericidal activity, but an SCN−/I−
ratio of 0.1 inhibits that bactericidal effect, and an SCN−/I−
ratio of 1 antagonizes it due to competition for oxidation and
faster decomposition of HOSCN in the presence of I− [14].
Against A. actinomycetemcomitans, the peroxidase system
with I−, Cl−, or a combination of I− and Cl− is effective but
addition of SCN− cancels the antibacterial effect [96]. On the





-LPO system has been shown against Candida
albicans, E. coli, S. aureus,Aspergillus niger, and Pseudomonas
aeruginosa [19, 97].
4. Conclusion
Themolecular evolution of heme peroxidases and the preser-
vation of their catalytic domain [6] show that the production
of strong oxidants is a powerful part of the nonimmune
defense mechanisms against pathogenic bacteria, fungi, or
parasite which made the use of those enzymes in practical
applications worthwhile.
The enzymatic reactions involving mammalian peroxi-
dases are complex and various molecules can promote or
reduce dramatically the antibacterial activity of the per-
oxidase system. In order to favor the halogenation cycle
required in in vitro and in vivo antimicrobial applications,
several points have to be taken into account: (i) to avoid the
presence of competitors to iodide or thiocyanate for binding
to Compound I and to avoid the presence of inhibitors





concentration which is able to destruct the enzyme
and to react with iodine or hypoiodite with loosing of active
molecules, (iii) to favor the presence of hypoiodite instead of
iodine due to the association reaction of iodine with iodide,
(iv) to avoid excess concentration of thiocyanate which can
inhibit formation of Compound I, (v) to use the entire
system (enzyme + substrates) instead of active molecules
alone, (vi) to favor moderate acid pH when hypothiocyanite
is the active molecule, (vii) for bactericidal, fungicidal, or
10 Enzyme Research
parasitical applications, the use of iodide has to be preferred,
(viii) the use of combined presence of iodide and thiocyanate
has to be checked carefully for efficacy, and (ix) to favor the
cofactor role of iodide or thiocyanate.
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